The Challenge: Innovation is moving faster than operational readiness
- Biotech innovation has never moved faster
- Early-stage risk isn’t always technical, it’s also operational
- Facility, utility, and manufacturing readiness often lag development
Why It Matters: Quality is inseparable from how therapies are produced
- Advanced therapies offer extraordinary therapeutic potential
- They also introduce higher operational and GMP risk
- Quality is intrinsically linked to process design, control, and execution
What’s Driving the Pressure: Advanced modalities are compressing timelines and increasing complexity
- Accelerated clinical pathways
- Platform technologies
- Novel modalities:
◦ Cell & gene therapies
◦ mRNA
◦ Viral vectors
◦ Combination products - Tighter integration of:
◦ Facilities
◦ Utilities
◦ Manufacturing processes
The Problem: CQV often starts too late
- Validation planning begins after key design decisions
- Inefficiencies compound over time
- Results include:
◦ Development delays
◦ Increased cost
◦ Inspection risk
◦ Suboptimal operations
The Opportunity: Start CQV early and treat it as a lifecycle discipline
- Day 1 clarity on the validation lifecycle
- Shift the mindset:
◦ From “Did we test everything?”
◦ To “Did we control what matters most?” - Focus effort on patient and product risk
The Impact: Strategic CQV accelerates time to market
- Facilities, utilities, and processes aligned to the validation lifecycle
- Faster transition from development to GMP manufacturing
- Stronger inspection readiness
- Reduced rework and delays
How Syner-G Helps
- Risk-Based Validation From the Start
- Anchor CQV in Product & Patient risk
- Align Validation to Phase-Appropriate GMP Expectations
The Result: From Process Science to GMP compliance
- Translate process intent into qualified systems
- Enable reliable, repeatable GMP operations
- Support clinical manufacturing, process performance qualification, and regulatory inspections
Syner-G helps organizations build documented, science-aligned, inspection-ready confidence that facilities, utilities, systems, and processes are ready to deliver advanced therapies to patients, safely and efficiently.
